References
- World Health Organization. Global tuberculosis control: surveillance, planning, financing: WHO report 2008. Geneva: WHO, 2008.
- Sriram D, Yogeeswari P, Dinakaran M, Thirumurugan R. Antimyco-bacterial activity of novel 1-(5-cyclobutyl-1,3-oxazol-2-yl)-3-(sub)phenyl/pyridylthiourea endowed with high activity toward multi-drug resistant tuberculosis. J Antimicrob Chemother 2007;59:1194–6.
- Sriram D, Senthilkumar P, Dinakaran M, Yogeeswari P, China A, Nagaraja V. Antimycobacterial activities of novel 1-(cyclopropyl/tert-butyl/4-fluorophenyl)-1,4-dihydro-6-nitro-4-oxo-7-(substituted secondary amino)-1,8-naphthyridine-3-carboxylic acid. J Med Chem 2007;50:6232–9.
- Kumar RR, Perumal S, Senthilkumar P, Yogeeswari P, Sriram D. Discovery of antimycobacterial spiro-piperidin-4-ones: an atom economic, stereoselective synthesis, and biological intervention. J Med Chem 2008; 51:5731–5.
- Dinakaran M, Senthilkumar P, Yogeeswari P, China A, Nagaraja V, Sriram D. Antimycobacterial and phototoxic evaluation of novel 6-fluoro/nitro-4-oxo-7-(sub)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid. Int J Antimicrob Agents 2008;31:337–44.
- Dinakaran M, Senthilkumar P, Yogeeswari P, China A, Nagaraja V, Sriram D. Novel ofloxacin derivatives: synthesis, antimycobacterial and toxicological evaluation. Bioorg Med Chem 2008;16:3408–18.
- Sriram D, Yogeeswari P, Thirumurugan R, Pavana RK. Discovery of newer antitubercular oxazolyl thiosemicarbazones. J Med Chem 2006; 49:3448–50.
- Dinakaran M, Senthilkumar P, Yogeeswari P, China A, Nagaraja V, Sriram D. Synthesis, antimycobacterial activities and phototoxic evaluation of 5H-thiazolo[3,2-a]quinoline-4-carboxylic acid derivatives. Med Chem 2008;4:482–91.
- Kumar RR, Perumal S, Senthilkumar P, Yogeeswari P, Sriram D. An atom efficient, solvent-free, green synthesis and antimycobacterial evaluation of 2-amino-6-methyl-4-aryl-8-[(E)-arylmethylidene]-5,6,7,8-tetrahydro-4H-pyrano[3,2-c]pyridine-3-carbonitriles. Bioorg Med Chem Lett 2007;17:6459–62.
- National Committee for Clinical Laboratory Standards. Antimyco-bacterial susceptibility testing for Mycobacterium tuberculosis. Proposed standard M24-T. Villanova, PA: National Committee for Clinical Laboratory Standards. 1995.
- Xie Z, Siddiqi N, Rubin ER. Differential antibiotic susceptibilities of starved Mycobacterium tuberculosis isolates. Anitimicrob Agents Chemother 2005;49:4778–80.
- Bai B, Xie JP, Yan JF, Wang H, Hu C. A high throughput screening approach to identify isocitrate lyase inhibitors from traditional Chinese medicine sources. Drug Dev Res 2006;67:818–23.
- Gundersen LL, Meyer NJ, Spilsberg B. Synthesis and antimycobacterial activity of 6-arylpurines: the requirements for the N-9 substituent in active antimycobacterial purines. J Med Chem 2002;45:1383–6.
- Jones G, Willett P, Glen RC, Leach AR, Taylor R. Development and validation of a genetic algorithm for flexible docking. J Mol Biol 1997; 267:727–48.
- Mc Kinney JD. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase. Nature 2000;406:735–8.
- Bentrup KHZ, Miczak A, Swenson DL, Russell DG. Characterization of activity and expression of isocitrate lyase in Mycobacterium avium and Mycobacterium tuberculosis. J Bacteriol 1999;181:7161–7.